Navigation Links
FDA: Do Not Feed SimplyThick to Premature Infants
Date:5/20/2011

tal early in their premature course. But among the ill babies of which FDA is aware, some had been discharged from the hospital to home on a feeding regimen that included SimplyThick and then fell ill at home.

What are the Symptoms of Illness/Injury?

NEC is a life-threatening condition characterized by inflammation and death of intestinal tissue. The condition is most often diagnosed in babies who are born prematurely.

Signs and symptoms of NEC include appearance of a bloated abdominal area, appearance of illness, feeding intolerance, greenish-tinged (bile) vomiting and bloody stools.

Who is at Risk?

Premature infants currently receiving hospital care and premature infants discharged from the hospital within the past 30 days should not be fed SimplyThick.

What Do Parents, Care Givers and Health care Providers Need To Do?  

Do not feed SimplyThick to premature infants.

Parents and caregivers who have questions or concerns related to the use of the product and/or who have medical concerns should contact their health care provider.

What Does the Product Look Like?

SimplyThick is one brand of thickening agent available to medical centers and consumers. The product is sold in packets of individual servings and in 64-ounce dispenser bottles. The product can be purchased from distributors and local pharmacies throughout the United States.

Images of the product label can be found here.

Where is it Distributed?

SimplyThick is distributed and can be purchased throughout the United States.

What is Being Done about the Problem?

FDA is actively investigating the link between SimplyThick and these illnesses and deaths. FDA will provide updates as information is made available.

Who Should be Contacted?

Parents and caregivers who ha
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births
2. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
3. Pivotal Data for the Investigational Treatment PSD502 for Primary Premature Ejaculation in the United States to be Presented at Major Medical Meeting
4. New Multi-Center Study Finds Clinical Practice Change with Masimo SET Pulse Oximetry Reduces Severe Eye Damage More Than 50% in Premature Newborns
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
7. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
8. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
9. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
10. Omega-3 Fatty Acids Critical to Infants, Mothers and the Seriously Ill
11. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014 Research ... "PCSK9 and Other Novel Hypercholesterolemia Drugs" report ... that there is a high cholesterol burden despite the ... of all the available options, statins have been ubiquitously ... that reduction of plasma LDL cholesterol (LDLC) is the ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014  Elusys ... therapies to treat infectious disease, today announced it ... safety studies of obiltoxaximab (ETI-204). Obiltoxaximab is an ... anthrax and data from these studies support the ... intravenously (IV) at the intended therapeutic dose. The ...
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
Breaking Medicine Technology:PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
... Feb. 23, 2011 Plexus Biomedical Inc. has been ... and Drug Administration to market the first device clinically ... Hemorrhoids associated with vaginal delivery are a frequent complication ... women in the U.S. every year. The ...
... Inc. (Nasdaq: MAPP ) today announced that the ... Citi,s 2011 Global Healthcare Conference , Wednesday, March 2, at ... , Thursday, March 3, at 10:00 a.m. ET in ... March 9, at 10:15 a.m. ET in BostonBarclays Capital 2011 ...
Cached Medicine Technology:Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth 2
(Date:9/22/2014)... September 22, 2014 WHO: LiveOps, ... and customer service solutions. , WHAT: The 10th ... on customer care for the connected consumer. Constant ... to offer new challenges and opportunities for customer ... attendees identify best practices, network and learn from ...
(Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
(Date:9/22/2014)... Tara Haelle ... News) -- Measuring how quickly a child,s brain processes ... to a new study. Observing children,s brainwaves ... currently possible, the study authors reported. "The finding ... is associated with autism severity is hugely promising," said ...
(Date:9/22/2014)... September 22, 2014 The “ Ztylus ” ... Tech Report , which reviews and features the latest technology ... of NewsWatch and technology expert, conducted the review and shared ... snap-in lens kit that gives users four lens options for ... part of its monthly Tech Report, which reviews and features ...
(Date:9/22/2014)... Medical experts this past weekend gathered ... discuss brain-related diseases facing an aging population, including ... disorders. , Each of the 50 attendees ... memory care community or hospice office. Silverado, with ... hosts the annual event to facilitate the exchange ...
Breaking Medicine News(10 mins):Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:NewsWatch Recently Featured the Phone Case “Ztylus” on National Television 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... receive fewer blood transfusions do just as well as those ... of blood transfusions varies widely among U.S. hospitals. The ... Journal of the American Medical Association . In ...
... murine leukemia virusrelated virus (XMRV) has been the subject ... conflicting reports have created an unclear picture of XMRV,s ... in the November 15 issue of The Journal ... supports a possible link between XMRV and prostate cancer ...
... molecule they designed can block activation of a gene in ... those cancer cells to survive chemotherapy. Without the ... to be protected from the toxic effects of chemotherapy drugs. ... protecting the cells, the research suggests. As a result, more ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, Oct. ... cancer patients treated with bisphosphonate drugs such as Aredia or ... be at higher risk for the irregular heartbeat known as ... atrial fibrillation, the upper chambers of the heart beat chaotically, ...
... results of a large Phase-III clinical trial have shown ... with a hard-to-treat group of rare cancers that affect ... the European Society for Medical Oncology (ESMO), Dr Marianne ... everolimus improved progression-free survival by 5.1 months in patients ...
... of breast cancer can lead some women to wonder if ... of more than 85,000 postmenopausal women, published in BioMed Central,s ... regular physical activity, maintaining a healthy weight, and drinking less ... a family history of the disease. The University of ...
Cached Medicine News:Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Blocking an oncogene in liver cancer could be potential therapy option 2Health News:Blocking an oncogene in liver cancer could be potential therapy option 3Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 2Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
... first steps any hospital or health system ... powerful, most effective tools available for physicians ... clinician documentation and electronic medical record (EMR) ... this goal. In fact, its the most ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
... ChartingPlus proves itself to over 2,000 medical ... with the user in mind, ChartingPlus relies ... and dynamic features to improve documentation quality ... Our medical content is specific ...
Medicine Products: